

Fotis Nikolos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6521521/publications.pdf>

Version: 2024-02-01

17
papers

605
citations

759233

12
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1061
citing authors

#	ARTICLE	IF	CITATIONS
1	Intercepting IRE1 kinaseâ€FMRP signaling prevents atherosclerosis progression. <i>EMBO Molecular Medicine</i> , 2022, 14, e15344.	6.9	10
2	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	12.8	17
3	Inhibitory DAMPs in immunogenic cell death and its clinical implications. <i>Cell Stress</i> , 2021, 5, 52-54.	3.2	6
4	Estrogen Receptor β -Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. <i>Cancer Research</i> , 2021, 81, 2399-2414.	0.9	7
5	Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. <i>Nature Communications</i> , 2020, 11, 6299.	12.8	128
6	Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. <i>Nature Communications</i> , 2019, 10, 2131.	12.8	27
7	GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. <i>Endocrine-Related Cancer</i> , 2018, 25, 453-469.	3.1	48
8	Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 448-459.	6.3	112
9	ER β Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. <i>Molecular Cancer Research</i> , 2018, 16, 233-242.	3.4	14
10	ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. , 2018, 59, 132.		20
11	ER β alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. <i>Oncotarget</i> , 2018, 9, 22509-22522.	1.8	19
12	Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. <i>Breast Cancer Research</i> , 2017, 19, 79.	5.0	20
13	ER β decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. <i>Oncotarget</i> , 2016, 7, 13599-13611.	1.8	39
14	Pleiotropic signaling evoked by tumor necrosis factor in podocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F98-F108.	2.7	6
15	ER β decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. <i>Oncogene</i> , 2015, 34, 4130-4141.	5.9	45
16	ER β Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling. <i>Molecular Cancer Research</i> , 2014, 12, 843-854.	3.4	14
17	ER β 1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. <i>Breast Cancer Research</i> , 2012, 14, R148.	5.0	73